血色病相关HFE p.C282Y纯合子肝脏并发症发生率:中心性肥胖的作用
在1297名男性和1602名女性HFE p.C282Y+/+参与者中,平均随访13.3年,高腰臀比与肝纤维化/肝硬化、肝癌、非酒精性脂肪性肝病及2型糖尿病风险升高相关;男性高腰臀比(≥0.96)肝纤维化/肝硬化风险比为4.13,女性高腰臀比(≥0.85)为9.17。
要点
- p.C282Y+/+男性高腰臀比(≥0.96)肝纤维化/肝硬化风险比为4.13(95%CI 2.04-8.39)。
- p.C282Y+/+女性高腰臀比(≥0.85)肝纤维化/肝硬化风险比为9.17(95%CI 2.51-33.50)。
- 男性高腰臀比组80岁累积肝纤维化/肝硬化发生率为15.0% vs 3.9%。
核心结论
- 在p.C282Y+/+男性和女性中,腰臀比增加与肝脏并发症风险显著升高相关。
- 作者建议应测试减少中心性肥胖以改善这些结局的干预措施。
研究设计与样本
- 英国生物银行社区队列中p.C282Y+/+参与者,基线腰臀比数据可用者1297名男性和1602名女性,平均随访13.3年。
- 采用样条回归和Cox比例风险模型,校正年龄和遗传主成分。
主要发现
- p.C282Y+/+男性腰臀比与医院住院诊断的肝纤维化/肝硬化(p=2.4×10^-5)、肝癌(p=0.007)、非酒精性脂肪性肝病(p=7.7×10^-11)和2型糖尿病(p=5.1×10^-16)呈正线性关系。
- p.C282Y+/+男性高腰臀比(≥0.96;33.9%)肝纤维化/肝硬化风险比为4.13(95%CI 2.04-8.39,p=8.4×10^-5 vs 正常腰臀比),80岁累积发生率为15.0%(95%CI 9.8%-22.6%)vs 3.9%(95%CI 1.9%-7.6%)。
- p.C282Y+/+男性高腰臀比组肝癌累积发生率为9.2%(95%CI 5.7%-14.6%)vs 3.6%(95%CI 1.9%-6.6%)。
- 24名高腰臀比p.C282Y+/+男性中发生肝纤维化/肝硬化者,23名(96%)被诊断为血色病。
- p.C282Y+/+女性高腰臀比(≥0.85;30.0%)肝纤维化/肝硬化风险比为9.17(95%CI 2.51-33.50,p=3.8×10^-7),非酒精性脂肪性肝病风险比为5.17(95%CI 2.48-10.78,p=1.2×10^-5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The HFE p.C282Y+/+ (homozygous) genotype and central adiposity both increase liver disease and diabetes risks, but the combined effects are unclear. We estimated waist-to-hip ratio (WHR) associations with incident clinical outcomes in routine care in p.C282Y+/+ participants in the UK Biobank community cohort. APPROACH AND RESULTS: Baseline WHR data available in 1297 male and 1602 female p.C282Y+/+ with 13.3-year mean follow-up for diagnoses. Spline regressions and Cox proportional hazard models were adjusted for age and genetic principal components. Cumulative incidence was from age 40 to 80 years. In p.C282Y+/+ males, there were positive linear WHR relationships for hospital inpatient-diagnosed liver fibrosis/cirrhosis ( p = 2.4 × 10 -5 ), liver cancer ( p = 0.007), non-alcoholic fatty liver disease ( p = 7.7 × 10 -11 ), and type 2 diabetes ( p = 5.1 × 10 -16 ). The hazard ratio for high WHR in p.C282Y+/+ males (≥0.96; 33.9%) was 4.13 for liver fibrosis/cirrhosis (95% CI: 2.04-8.39, p = 8.4 × 10 -5 vs. normal WHR); cumulative age 80 incidence 15.0% (95% CI: 9.8%-22.6%) versus 3.9% (95% CI: 1.9%-7.6%); for liver cancer, cumulative incidence was 9.2% (95% CI: 5.7%-14.6%) versus 3.6% (95% CI: 1.9%-6.6%). Hemochromatosis was diagnosed in 23 (96%) of the 24 high WHR p.C282Y+/+ males with incident fibrosis/cirrhosis. High WHR (≥0.85; 30.0%) p.C282Y+/+ females had raised hazards for liver fibrosis/cirrhosis (hazard ratio = 9.17, 95% CI: 2.51-33.50, p = 3.8 × 10 -7 ) and Non-alcoholic fatty liver disease (hazard ratio = 5.17, 95% CI: 2.48-10.78, p = 1.2 × 10 -5 ). Fibrosis/cirrhosis associations were similar in the subset with additional primary care diagnoses. CONCLUSIONS: In p.C282Y+/+ males and females, increasing WHR is associated with substantially higher risks of liver complications. Interventions to reduce central adiposity to improve these outcomes should be tested.
引用
- Lucas MR, Pilling LC, Atkins JL, et al. Incidence of liver complications with hemochromatosis-associated HFE p.C282Y homozygosity: The role of central adiposity. Hepatology. 2024. PMID: 39178373. doi:10.1097/HEP.0000000000001056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。